Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Organisation › Details

2cureX (Group)

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor and the treatment to which the patient is resistant. Immediately after the test, the patient can be offered the selected treatment. IndiTreat® is presently being introduced into the European market. The aspiration is that IndiTreat® becomes a standard Functional Precision Medicine tool for cancer patients. The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol: “2CUREX”). *


Period Start 2006-12-10 splitoff
  Today 2cureX ApS
  Predecessor Carlsberg Research Center
Products Industry drug discovery
  Industry 2 ChemoCellomics® technology
Persons Person Thastrup, Ole (2cureX 202102– CSO + Deputy-CEO before 200612–2020101 CEO + Co-founder + Co-owner)
  Person 2 Jessen, Timm-Heinrich (Topas Therapeutics 201510–202007 Managing Director before Bionamics + Scienamics RESIGNED 7/20)
Region Region Birkerød
  Country Denmark
  City n. a. Copenhagen
    Address record changed: 2021-04-08
Basic data Employees n. a.
    * Document for »About Section«: 2cureX AB. (1/28/21). "Press Release: 2cureX Appoints Kenneth Graabek Johansen, an Experienced Business and Financial Executive, as New CFO". Copenhagen.
Record changed: 2024-02-12


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for 2cureX (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top